Regeneron Pharmaceuticals is a healthcare company focusing on discovering, developing, and commercializing pharmaceutical products for the treatment of serious medical conditions. Founded in 1988 and headquartered in New York, the company has therapeutic candidates in clinical trials for cancer, eye diseases, and inflammatory diseases, as well as preclinical programs in other diseases and disorders. Their product portfolio includes EYLEA, ARCALYST, ZALTRAP, trap fusion proteins, and fully human monoclonal antibodies. In collaboration with Sanofi, Regeneron is also developing a new cholesterol drug that aims to reduce cholesterol levels by up to 72%.
The company has an employee size of 9,123 and an annual revenue of $12.2 billion. Regeneron's diverse workforce is 45.6% female and 46.1% ethnic minorities, with a high proportion of employees being members of the Democratic Party. With an average annual employee salary of $85,589, Regeneron has a strong employee retention rate, with staff members typically staying with the company for 3.8 years. As a key player in the healthcare industry, Regeneron continues to make strides in the development and commercialization of innovative pharmaceuticals.
